Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (September 22nd Preview)
-
Autoimmune therapy advancement in Sjögren’s disease
Amgen reported preliminary Phase 3 success for dazodalibep in Sjögren’s disease, setting up a potential first targeted therapy for a condition that currently has no approved treatments. The fusion protein achieved statistically significant and clinically meaningful results in the study, according to the company’s update. The readout also positions dazodalibep against established competitors in the autoimmune space and raises the odds of an FDA review milestone for a first-in-class mechanism. Amgen’s Sjögren’s pipeline momentum is tied to the broader Horizon Therapeutics acquisition, under which dazodalibep was acquired. Investors and clinicians will now watch for the next late-stage trial results and for what endpoints will be prioritized in regulatory discussions, as Sjögren’s becomes a key autoimmune proving ground for immunomodulatory biologics.
-
FDA decision pressure on ALS drug pathway
Otsuka and Ionis Pharmaceuticals advanced their amyotrophic lateral sclerosis program after a Phase 3 study hit its primary endpoint. The result positions the partners to seek expedited regulatory pathways, with discussions now expected as the clinical evidence packet moves toward submission. The therapy, ulefnersen, is an RNA-based drug targeting a rare ALS subtype. The next steps are likely to focus on durability of effect and safety monitoring, particularly given the high bar for benefit in ALS. For the ALS market, the update matters because it changes the near-term probability of a new disease-modifying option and may influence how clinicians sequence emerging RNA therapeutics.
-
Radiopharma consolidation accelerates with Telix–ITM merger
Telix agreed to acquire ITM Isotope Technologies Munich in a deal worth up to $2.35 billion, aiming to secure isotope supply and scale manufacturing capacity as radiopharmaceutical competition intensifies. The structure includes about $1.65 billion upfront consideration, plus up to $700 million in regulatory and sales-linked milestones for ITM-11 (¹⁷⁷Lu-edotreotide). The transaction is intended to create a vertically integrated radiopharmaceutical platform spanning development, manufacturing, and distribution, with ITM’s Phase 3 experience adding late-stage depth to Telix’s oncology pipeline. Regulatory risk remains, including the need to address ITM’s prior U.S. FDA Complete Response Letter on chemistry, manufacturing and controls and third-party facility items. Telix’s execution will be closely watched for timelines to close and for CMC remediation sufficiency.
-
Emerging gene therapy approval track in X-linked retinitis pigmentosa
Beacon Therapeutics reported pivotal progress for laruparetigene zovaparvovec (laru-zova) in X-linked retinitis pigmentosa, describing a Phase 2/3 outcome that met the FDA-endorsed primary endpoint in the VISTA study. The company said improvement on low-luminance visual acuity favored both high- and low-dose cohorts, with responder proportions exceeding the untreated control group. The update strengthens the product’s path toward a biologics license application, as Beacon frames the result as a step closer to approval for a rare, vision-threatening condition. Investors will now focus on the durability of visual function gains and the evidence package required for labeling. Beacon’s readout arrives during a competitive gene therapy period for ocular indications, where manufacturing readiness and clinical consistency remain central to regulatory review.
-
RNA splicing deal bets on precision oncology targets
Envisagenics and Boehringer Ingelheim inked a multi-target, option-style collaboration valued at up to $1 billion-plus, centered on Envisagenics’ alternative RNA splicing SpliceCore platform. Boehringer will fund research to validate tumor-specific targets derived from splice events, with an option to license selected targets once programs conclude. The arrangement aims to expand the therapeutic modality menu for tumor-selective targets, spanning antibodies and multispecific formats, while offering Envisagenics non-dilutive funding to support its pipeline. The deal also reinforces the expanding use of transcriptome-based target discovery in solid tumors. Envisagenics framed the pact as financial flexibility while validating SpliceCore’s output for partner translation, putting tumor-specific splicing biology at the center of the next wave of precision oncology negotiations.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.